By Dr Michael Klein, Founder & Chief Executive Officer
A growing chorus of predictions holds that artificial intelligence will replace pharmaceutical sales representatives within the next decade. The logic is straightforward: if AI can personalise content, analyse prescribing data, predict customer preferences, and deliver information through digital channels at scale, what value does a human representative add?
The question deserves a serious answer, not a defensive one. I have spent enough of my career working with pharmaceutical commercial teams to believe that the conventional framing is wrong. AI will change the role of the pharmaceutical sales representative. It will not eliminate it. The representatives who adapt will become more valuable. Those who do not will struggle. But the ones who survive and thrive will not succeed by doing what AI does better. They will succeed by doing what AI cannot do at all.
Let me be specific about where AI has an edge. AI systems process structured data at a scale and speed no human can match. They can analyse prescribing patterns across thousands of healthcare providers, identify segments with the highest unmet need, and recommend next-best-action protocols based on what worked with similar customers. They can generate compliant promotional content tailored to individual physician preferences. They can handle routine queries through chat interfaces, schedule appointments, and follow up on samples and materials.
Several pharmaceutical companies are already deploying these capabilities. Novartis has invested in AI-powered content generation for its reps. Sanofi has developed an AI assistant for field teams that provides real-time data on customer interactions and prescribing trends. Pfizer used AI-driven analytics during its COVID-19 vaccine launch to prioritise healthcare provider outreach based on population health data. These are not speculative applications. They are in production and delivering measurable results.
The pattern is clear: any task that involves processing large volumes of data, generating standardised content, or executing routine interactions at scale is moving to AI. The return on investment is simply too strong for pharmaceutical companies to ignore.
The critical question is what remains after the routine tasks are automated. I would argue that what remains is the most valuable part of the pharmaceutical representative's role: the capacity to build trust, read a room, navigate complex professional relationships, and provide scientific insight that responds to a clinician's specific concerns in real time.
Consider the following scenario. A specialist physician has been treating patients with a particular therapy for several years. A new product enters the market with a mechanism of action that differs from anything the physician has used before. The representative's job is not to hand the physician a brochure or read from a script. It is to understand the physician's clinical experience, anticipate the questions that will arise when the physician considers prescribing the new therapy, and address them with scientific depth and personal credibility. The physician needs to trust that the representative understands the science, respects the clinical context, and will provide honest information about efficacy, safety, and patient selection.
That trust is relationship capital. It is built over multiple interactions, through demonstrated competence, reliability, and respect for the physician's autonomy. An AI can generate a credible clinical summary. It cannot build relationship capital. It cannot look a physician in the eye and answer an unasked question about a safety signal in a subgroup that the physician is worried about but has not mentioned. It cannot sense when a carefully prepared presentation is not landing and pivot to a different approach mid-conversation.
These are human capabilities and they matter more in pharmaceutical sales than in many other commercial roles because the consequences of getting it wrong are not limited to a lost sale. They include patient harm, liability, and damage to the prescribing physician's relationship with their own patients.
The pharmaceutical industry has been moving toward more scientific engagement models for years, well before AI became the dominant topic. Medical science liaisons (MSLs) now outnumber traditional sales representatives in many therapeutic areas, particularly in specialty care, oncology, and rare diseases. MSLs hold advanced degrees and engage with key opinion leaders on clinical data, emerging research, and therapeutic developments. They do not sell in the traditional sense. They educate, inform, and gather scientific intelligence.
This trend will accelerate. As products become more complex, as personalised medicine expands, and as healthcare providers expect deeper scientific dialogue from the pharmaceutical companies they interact with, the demand for representatives who can conduct that dialogue will grow. The representatives who survive AI-driven automation will be those who function more like MSLs than traditional sales representatives. They will need to understand clinical data, interpret study results, discuss guidelines, and provide insights that a physician cannot get from a digital channel or a chatbot.
That requires scientific literacy, clinical judgment, and the ability to hold a conversation with someone who may know more about the specific clinical context than the representative does. It requires intellectual humility and the confidence to say "I do not know" followed by "but I will find out and come back to you." AI cannot do that credibly because the follow-through is not a data point. It is a relational commitment.
Leading pharmaceutical companies have moved to omnichannel engagement models that integrate digital and human interactions into a coordinated experience. The premise is that different healthcare providers prefer different channels for different types of interactions. Some want brief digital updates for routine information and face-to-face meetings for complex discussions. Others prefer virtual meetings for everything. The channel choice depends on the provider's specialty, practice setting, personal preference, and the stage of their relationship with the product.
In an omnichannel model, AI powers the digital layer. It delivers personalised content, tracks engagement, and identifies when a human interaction is needed. It frees the representative from administrative and analytical work so they can focus on the interactions where human presence adds the most value. The representative's role shifts from being the primary information channel to being the relationship anchor who shows up when the information matters most.
This shift is already happening. Representatives in leading pharmaceutical companies spend less time on routing and scheduling and more time on preparation and follow-through. They use AI tools to understand physician preferences before meetings. They arrive better informed and more focused. The good representatives welcome this change because it lets them do what they are best at.
The pharmaceutical sales representative of 2030 will look different from the representative of 2020. Some things will be gone: the generic product pitch, the routine follow-up call, the cold visit to a physician's office, the manual reporting of activities and outcomes. AI will handle those.
Other things will be more important. Strategic account management across multiple stakeholders in a hospital system. Deep scientific dialogue with specialists who expect the representative to understand their clinical challenges. Cross-functional coordination with medical affairs, market access, and patient support teams. Insight gathering that feeds back into product strategy and clinical development. These are not tasks that AI automates. They are tasks that AI enables by providing representatives with better information and more time.
The pharmaceutical companies that succeed will be those that invest in both technology and talent. They will build AI capabilities that augment their commercial teams and they will develop their representatives into scientific engagement professionals with the skills the new model demands. The companies that view AI as a cost-cutting mechanism to reduce headcount will find themselves with fewer representatives, weaker relationships, and no competitive advantage, because their competitors will have the same AI tools and stronger relationships.
The future of pharmaceutical sales belongs to professionals who combine AI-enabled preparation, analytics, and personalisation with the human capabilities that no language model possesses: clinical judgment, professional integrity, emotional attunement, and the slow accumulation of trust that turns a business contact into a professional relationship.
Technology changes the tools. It does not change what pharmaceutical commercialisation has always required: the right product, the right evidence, and the right person having the right conversation with the right prescriber at the right time. AI makes that easier for the companies that understand it and harder for those that do not.
